Lilly's Evista has breast cancer benefits

Evista works to prevent and treat osteoporosis, but its manufacturer, Eli Lilly, found that it might also be useful for preventing one type of breast cancer. The drug's generic name is raloxifene.

According to a study of 10,000 women published in the Journal of the National Cancer Institute, those taking the drug were 55 percent less likely to develop a hormonal type of breast cancer than were women taking a placebo drug. The women in the study were looking to see if the drug would help prevent heart disease, but Evista had no positive findings in that arena.

Unlike bisphosphonates, Evista is a selective estrogen receptor modulator (SERM) and prevents osteoporosis by acting at the estrogen receptors. While it makes sense that its breast cancer benefits would likely be limited to estrogen-receptor-positive breast cancer, this is the first study validating that logic. Estrogen-receptor-positive breast cancer is the most common type of breast cancer.

- check out the Evista release for more

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.